China Meheco Group 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12...1213141516171819202122...212213»
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Journal:  Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters. (Pubmed Central) -  Aug 2, 2023   
    No additional inhibitory effect of Nirmatrelvir was observed compared to the strong transporter inhibition caused by Ritonavir. Our current in vitro results should help to estimate the potential drug-drug interactions of these newly developed agents during COVID-19 treatment.
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Review, Journal, Adverse events:  Neurological side effects and drug interactions of antiviral compounds against SARS-CoV-2. (Pubmed Central) -  Aug 1, 2023   
    Further studies are required to better evaluate their efficacy and adverse events in patients with concomitant neurological diseases. Moreover, evidence from real-world studies will complement the current knowledge.
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer
    Review, Journal:  Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19. (Pubmed Central) -  Aug 1, 2023   
    Comorbidity usage and pharmacovigilance will play a significant stake in the future of paxlovid development. Second-generation M inhibitors play an important role in the upcoming problems associated with COVID-19.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Phase classification, Enrollment change, Trial completion date, Trial initiation date:  RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms (clinicaltrials.gov) -  Jul 31, 2023   
    P2,  N=900, Not yet recruiting, 
    The binding of ESV to MPro also results in a significant, but smaller, increase in K and decrease in ?G and T, relative to NMV. Phase classification: P3 --> P2 | N=1700 --> 900 | Trial completion date: Jan 2024 --> Jul 2024 | Initiation date: Jan 2023 --> Jul 2023
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    A Rare Association of Protease Inhibitors With Acute Pancreatitis: A Case Report (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_3470;    
    We present a case of an association between the use of protease inhibitor (PI) Nirmatrelvir / Ritonavir prescribed to a patient diagnosed with COVID-19 infection; and the subsequent development of AP...Figure: Figure 1. CT scan showing evidence of Acute Pancreatitis.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Paxlovid-Induced Tacrolimus Toxicity in a Liver Transplant Patient (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_3078;    
    Treatment with phenytoin was successful...She also had an elevated Prograf level of 206 ng/ml (the normal range is 4 - 16 ng/ml)...The American Society of Transplantation recommends alternative therapy, and the National Institutes of Health suggests holding tacrolimus during Paxlovid treatment. Avoiding Paxlovid in people taking tacrolimus is crucial, if possible, due to the severe drug-to-drug interaction, as highlighted in our case.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Fatal Case of Nirmatrelvir/Ritonavir Induced Severe Liver Injury (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_1536;    
    In this case, a genetic mutation may have resulted in supratherapeutic and toxic levels of Paxlovid resulting in SLI. This is an important complication to report given that Paxlovid has not historically been shown to cause SLI.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    A Rare Case of Paxlovid-Induced Pancreatitis (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_590;    
    Our case report raises the awareness of the rare complication of pancreatitis from Paxlovid which has been utilized frequently with COVID-19 pandemic effects. Figure: CT Abdomen/Pelvis
  • ||||||||||  Olumiant (baricitinib) / Incyte, Eli Lilly, Paxlovid (nirmatrelvir and ritonavir) / Pfizer, azvudine (FNC) / Granlen
    Journal:  Composite Interventions on Outcomes of Severely and Critically Ill Patients with COVID-19 in Shanghai, China. (Pubmed Central) -  Jul 29, 2023   
    Treatment with an IL-6 receptor antagonist, baricitinib, and a-thymosin also had high probabilities of benefit in improving 2-month survival, among which a-thymosin could improve HRQoL. Treatment with Paxlovid, Azvudine, and therapeutic anticoagulation could significantly reduce disability at day 60.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Paxlovid (nirmatrelvir and ritonavir) / Pfizer
    Review, Journal:  Principles of Rational COVID-19 Therapy in Pediatrics. (Pubmed Central) -  Jul 29, 2023   
    In terms of frequency of occurrence, the leading positions are occupied by remdesivir and the combination of nirmatrelvir with ritonavir, as well as dexamethasone and tocilizumab. The paper emphasizes the relevance of research in the field of evaluating the effectiveness of individual treatment regimens as well as the analysis of the delayed consequences of pathology suffered in childhood under the conditions of using various approaches to pharmacotherapy.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI, Paxlovid (nirmatrelvir and ritonavir) / Pfizer
    Review, Journal:  Healing Treatments in COVID-19 Patients: A Narrative Review. (Pubmed Central) -  Jul 29, 2023   
    JAK inhibitors and anakinra have also gained an interest in some studies. As a conclusion of this narrative review, the best treatment strategy has yet to be defined and is likely to evolve in the future, not only because many other drugs are still under development and evaluation, but also because of the viral epidemics and epidemiology evolution.
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Review, Journal:  COVID-19: Variants, Immunity, and Therapeutics for Non-Hospitalized Patients. (Pubmed Central) -  Jul 29, 2023   
    We explore aspects of the immune response in a condensed discussion to understand B and T cell lymphocyte regulatory mechanisms and antibody effectiveness and senescence. Finally, COVID-19 therapies including Paxlovid, Remdisivir, Molnupiravir and convalescent plasma in non-hospitalized patients are presented with limitations for identification, collection, and distribution to infected patients.
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer
    PK/PD data, Review, Journal:  Potential pharmacokinetic interactions with concurrent use of herbal medicines and a ritonavir-boosted COVID-19 protease inhibitor in low and middle-income countries. (Pubmed Central) -  Jul 28, 2023   
    This review presents data on regionally-relevant herbal medicine use (particularly those promoted as treatments for COVID-19) and mechanism of action data on herbal medicines to highlight the potential for herbal medicine interaction Herb-drug interaction mediated by ritonavir-boosted antiviral protease inhibitors This work highlights potential areas for future experimental studies and data collection, identifies herbal medicines for inclusion in future listings of regionally diverse potential HDIs and underscores areas for LMIC-focused provider-patient communication. This overview is presented to support governments and health protection entities as they prepare for an increase of availability and use of Paxlovid